Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis Dupixent 300 mg weekly is the only biologic medicine to show positive, clinically meaningful Phase 3 results… Read More
TORONTO – Fasken confirmed today its sponsorship agreement with Black Boys Code (BBC), a non-profit organization dedicated to introducing Black youth to the STEM (science, technology, engineering and mathematics) disciplines with… Read More
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction FDA approval… Read More
A vaccine manufactured in plants and developed in Canada LONDON, U.K. — Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted… Read More
In U-EXCEL, the second of two Phase 3 induction studies, a significantly higher proportion of patients with moderate to severe Crohn’s disease treated with upadacitinib (45 mg once daily for… Read More
